- Home
- AQB vs PTIX Comparison
AQB vs PTIX Comparison
Compare AQB & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQB
- PTIX
- Stock Information
- Founded
- AQB 1991
- PTIX 1994
- Country
- AQB United States
- PTIX United States
- Employees
- AQB N/A
- PTIX N/A
- Industry
- AQB
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- AQB
- PTIX Health Care
- Exchange
- AQB Nasdaq
- PTIX Nasdaq
- Market Cap
- AQB 3.0M
- PTIX 3.2M
- IPO Year
- AQB N/A
- PTIX 2016
- Fundamental
- Price
- AQB $0.75
- PTIX $0.37
- Analyst Decision
- AQB Hold
- PTIX
- Analyst Count
- AQB 2
- PTIX 0
- Target Price
- AQB N/A
- PTIX N/A
- AVG Volume (30 Days)
- AQB 221.1K
- PTIX 331.1K
- Earning Date
- AQB 11-05-2024
- PTIX 03-31-2025
- Dividend Yield
- AQB N/A
- PTIX N/A
- EPS Growth
- AQB N/A
- PTIX N/A
- EPS
- AQB N/A
- PTIX N/A
- Revenue
- AQB $1,258,512.00
- PTIX N/A
- Revenue This Year
- AQB N/A
- PTIX N/A
- Revenue Next Year
- AQB $43.65
- PTIX N/A
- P/E Ratio
- AQB N/A
- PTIX N/A
- Revenue Growth
- AQB N/A
- PTIX N/A
- 52 Week Low
- AQB $0.47
- PTIX $0.35
- 52 Week High
- AQB $2.79
- PTIX $1.87
- Technical
- Relative Strength Index (RSI)
- AQB 50.10
- PTIX 38.67
- Support Level
- AQB $0.68
- PTIX $0.36
- Resistance Level
- AQB $0.98
- PTIX $0.44
- Average True Range (ATR)
- AQB 0.09
- PTIX 0.06
- MACD
- AQB -0.00
- PTIX -0.01
- Stochastic Oscillator
- AQB 33.93
- PTIX 6.69
About AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.